Regadenoson + Placebo
ApprovedCompleted 1 views this week 0 watching⚡ Active
Interest: 43/100
43
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Kidney Diseases
Conditions
Kidney Diseases, Coronary Artery Disease
Trial Timeline
Apr 1, 2009 → Dec 1, 2009
NCT ID
NCT00863707About Regadenoson + Placebo
Regadenoson + Placebo is a approved stage product being developed by Astellas Pharma for Kidney Diseases. The current trial status is completed. This product is registered under clinical trial identifier NCT00863707. Target conditions include Kidney Diseases, Coronary Artery Disease.
What happened to similar drugs?
20 of 20 similar drugs in Kidney Diseases were approved
Approved (20) Terminated (1) Active (0)
✅basiliximab + rabbit anti-thymocyte globulin + tacrolimus + alemtuzumab + mycophenolate mofetil + steroidsAstellas PharmaApproved
Hype Score Breakdown
Clinical
20
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (3)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01918995 | Phase 1 | Completed |
| NCT00862641 | Approved | Completed |
| NCT00863707 | Approved | Completed |
Competing Products
20 competing products in Kidney Diseases